Navigation Links
OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
Date:6/24/2009

BOTHELL, WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company has reached an agreement with the U.S. Food and Drug Administration (FDA) via the special protocol assessment process (SPA) on an amendment to the design of a Phase 3 registration trial of OGX-011, its lead product candidate targeting castrate resistant prostate cancer (CRPC). The FDA has agreed on modifications to the study population of a previously reviewed Phase 3 trial featuring survival as the primary endpoint. The study population has been modified to evaluate patients receiving first-line chemotherapy, rather than those receiving second-line chemotherapy. FDA agreed that the amended protocol adequately addresses the objectives necessary to support a regulatory submission.

"We are now ready to proceed with two Phase 3 trial designs from the FDA via the SPA process, one in first-line and one in second-line treatment of advanced prostate cancer," said Scott Cormack, President and CEO of OncoGenex Pharmaceuticals. "The trial for first-line treatment evaluates overall survival benefit for OGX-011 while the trial for second-line treatment evaluates for a durable pain palliation benefit. Based on the robustness of the OGX-011 survival benefit observed in the randomized Phase 2 trial for first-line docetaxel treatment, we felt evaluating both of these patient populations, as well as both endpoints, in our Phase 3 trials better positions the availability of OGX-011 treatment to a larger number of men with prostate cancer."

The Phase 3 trial has been designed in collaboration with internationally recognized experts in the treatment of patients with castrate resistant prostate cancer (CRPC) including Dr. Celestia Higano at the University of Washington and Dr. Kim Chi at the University of British Co
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
3. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
4. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
5. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
6. OncoGenex Reports First Quarter Financial Results
7. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
8. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
9. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
10. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
11. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...nker.comannouncesthatanewmarketresearchreportisava...tAnalysisandForecaststo2013 ,, http://www.rep...alysis-and-Forecasts-to-2013.html ,, BrazilBio...mary ,, Thereportprovidesdetailedanalysisandfo...thanolmarketinparticular.Italsohelpsinanalyzingand...
(Date:11/24/2009)...tment bank KTA Capital,s client Neuren Pharmaceuti...tible note private placement with a U.S. instituti...by KTA Capital as Neuren,s exclusive placement age...k (PRWEB) November 23, 2009 -- The independent New...Capital") has announced that its client Neure...
(Date:11/24/2009)...yment grew by 29,000 jobs in October, and the fie...during the U.S. recession. However, clinics and sp...stems are coming closer to having to actually cut ... , (Vocus) November 24, 2... October despite the shedding of jobs in most othe...
(Date:11/24/2009)...leEnergyCorp.announcedtodaythatthecompanyandtheOde...rded$2millionbyWashingtonState,sCommunityEconomicR...iptoconstructthestate,sfirstspecialtybiochemicalbi...willsignificantlyspeedthedevelopmentofourbiorefine...MarbleEnergyCEOKellyOgilvie."WearegratefultotheGov...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...ISON, N.J., June 9 Davie Floyd, Director of Train...roup, an Informed Medical,Communications company, ...&,Biotech Trainers 37th Annual Conference in Orlan... through influential dialogue, Floyd and Bresette,...ialogue: Advanced,Influencing Skill for Changing T...
...dustry veteran joins growing specialty online empl... expansion, FORT WORTH, Texas, June 9 onTargetj... announced today the appointment of,Michael J. "Mi...ighted to be part of the onTargetjobs team as it i... said Mr. Tansey. "The acquisition of,RegionalHelp...
...YMOUTH MEETING, Pa., June 9 /Xinhua-PRNewswire-Fir... ) ("BMP Sunstone" or the "Company") today,announc...unstone,Corporation and a member of the Board of D...f Operating Officer of BMP Sunstone Corporation,ef...dent of BMP Sunstone since April 2008 and,played a...
Other Biology Technology:Experts From The Peer Group Provide Training on Dialogue-Based Influence at the SPBT Annual Conference 2onTargetjobs Announces Appointment of Michael Tansey as New CEO 2BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer 2BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer 3
(Date:11/24/2009)... NEW YORK (November 24, 2009) -- The Wildl...eport revealing that the last remaining population...tly due to the rising tide of poaching and habitat...lp inform Russian officials of what needs to be do... biggest cat. , The report was rele...
(Date:11/24/2009)...onstitutes fish food is a matter of debate. A high... get almost 50 percent of their carbon from trees ... the terrestrial and aquatic ecosystems. , But n...s this is not likely to be true. Algae provide a m...ccording to research published this week in the P...
(Date:11/24/2009)...elease is available in Spanish . , The pres...evels of inflammatory substances in the blood, hin...hown by a research project of the University of Na...entist at the School of Pharmacy. , The project,...n relation to the control of body weight and infla...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3It can be predicted the reaction obese patients will have to a diet 2Vermont Receives National Award for Physician e Prescribing Thanks to Efforts by Local Healthcare Firm 49668 1Vermont Receives National Award for Physician e Prescribing Thanks to Efforts by Local Healthcare Firm 49668 2Veterans From Iraq Afghanistan 26 Other Conflicts Partner With Service Dogs in Americas VetDogs Graduation Ceremony 49663 1Veterans From Iraq Afghanistan 26 Other Conflicts Partner With Service Dogs in Americas VetDogs Graduation Ceremony 49663 2VA Secretary Hits the Road to Highlight 22United We Serve 22 Effort 49658 1VA Secretary Hits the Road to Highlight 22United We Serve 22 Effort 49658 2
... Without them, birds could not fly or attract mate...xperimentally testing one current hypothesis, deve...dical School believe they now have the answer. , I...allon and his team showed that Sonic hedgehog (Shh...expressed in order to produce barb ridges, which a...
... the arrival of the first humans in ancient Austra...Carnegie Institution, University of Colorado, Aust...e extinctions occurred 45,000 to 55,000 years ago....nvironment contained in ancient eggshells and womb...t what happened. The remains showed evidence of a ...
... understood disease agents involved in causing hor...acob disease in people, mad cow disease in cattle ...new research suggests that a variant form of abnor...e cell membrane--may be unable to signal cells to ...entists at the Rocky Mountain Laboratories (RML), ...
Other Biology News:Molecular mechanism of feather formation found 2Molecular mechanism of feather formation found 3Did humans cause ecosystem collapse in ancient Australia? 2Variant prion protein causes infection but no symptoms 2
Chloramphenicol Acetyltransferase Fluorometric (BODIPY) Assay Kit, FAST CAT from Molecular Probes (Invitrogen)
Polyethylene Glycol 8000 from GE Healthcare, formerly Amersham Biosciences
Panomer 9 random oligodeoxynucleotide, Alexa Fluor 647 conjugate from Molecular Probes (Invitrogen)
GIBCO Chicken Serum from Invitrogen
Biology Products: